{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:35Z","timestamp":1787020175033,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11796-4","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:56:53Z","timestamp":1761299813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and associated risk factors of anti-tuberculosis drug induced liver injury among TB patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Vincent","family":"Nyangwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyaad","family":"Waja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn","family":"Thelingwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raadhiya","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziska","family":"Pretorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitumetse","family":"Majoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Boyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekiwe","family":"Ncwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananyo","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collen","family":"Masimirembwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"11796_CR1","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: WHO. 2024.ISBN 978-92-4-010153-1."},{"key":"11796_CR2","doi-asserted-by":"crossref","unstructured":"Jain N, Sharma D, Jain NK. Newer research transforming 24-month treatment of MDR\/ XDR-TB TO 6 months. Lung India. Wolters Kluwer Medknow Publications. 2025;42:140\u20136.","DOI":"10.4103\/lungindia.lungindia_431_24"},{"key":"11796_CR3","doi-asserted-by":"crossref","unstructured":"Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study. Med Sci Monit: Int Med J Exp Clin Res. 2020;26:e920350\u20131.","DOI":"10.12659\/MSM.920350"},{"key":"11796_CR4","doi-asserted-by":"crossref","unstructured":"Abbara A, Chitty S, Roe JK, Ghani R, Collin SM, Ritchie A, Kon OM, Dzvova J, Davidson H, Edwards TE, Hateley C. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017;17(1):231.","DOI":"10.1186\/s12879-017-2330-z"},{"key":"11796_CR5","doi-asserted-by":"crossref","unstructured":"Zhong T, Fan Y, Dong XL, Guo X, Wong KH, Wong WT, He D, Liu S. An investigation of the risk factors associated with anti-tuberculosis drug-induced liver injury or abnormal liver functioning in 757 patients with pulmonary tuberculosis. Front Pharmacol. 2021;12:708522.","DOI":"10.3389\/fphar.2021.708522"},{"key":"11796_CR6","doi-asserted-by":"crossref","unstructured":"Cavaco MJ, Alcobia C, Oliveiros B, Mesquita LA, Carvalho A, Matos F, Carvalho JM, Villar M, Duarte R, Mendes J, Ribeiro C. Clinical and genetic risk factors for drug-induced liver injury associated with anti-tuberculosis treatment\u2014a study from patients of Portuguese health centers. J Pers Med. 2022;12(5):790.","DOI":"10.3390\/jpm12050790"},{"issue":"39","key":"11796_CR7","first-page":"E30955","volume":"101","author":"YC Wang","year":"2022","unstructured":"Wang YC, Chen KH, Chen YL, Lin SW, Liu W, Da, Wang JT, et al. Pyrazinamide related prolonged drug-induced liver injury: A case report. Med (United States). 2022;101(39):E30955.","journal-title":"Med (United States)"},{"key":"11796_CR8","doi-asserted-by":"crossref","unstructured":"Xiao Y, Chen Y, Huang R, Jiang F, Zhou J, Yang T. Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study. BMC Med Res Methodol. 2024;24(1):92.","DOI":"10.1186\/s12874-024-02214-5"},{"issue":"2","key":"11796_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12072-023-10633-7","volume":"18","author":"Y Mao","year":"2024","unstructured":"Mao Y, Ma S, Liu C, Liu X, Su M, Li D, et al. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. Hepatol Int. 2024;18(2):384\u2013419.","journal-title":"Hepatol Int"},{"key":"11796_CR10","doi-asserted-by":"crossref","unstructured":"Liu Q, Guo D, Yu M, Tang D, Zhang Y, Luo M, He J. Clinical characteristics and risk factors for antituberculosis drug\u2010induced hypersensitivity. Br J Clin Pharmacol. 2025;91(1):134\u201342.","DOI":"10.1111\/bcp.16228"},{"key":"11796_CR11","doi-asserted-by":"crossref","unstructured":"Qi CC, Xu LR, Zhao CJ, Zhang HY, Li QY, Liu MJ, Zhang YX, Tang Z, Ma XX. Prevalence and risk factors of tuberculosis among people living with HIV\/AIDS in China: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):584.","DOI":"10.1186\/s12879-023-08575-4"},{"key":"11796_CR12","first-page":"1","volume":"13","author":"Y Molla","year":"2021","unstructured":"Molla Y, Wubetu M, Dessie B. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med. 2021;13:1\u20138.","journal-title":"Hepat Med"},{"key":"11796_CR13","doi-asserted-by":"crossref","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society\/Centers for disease control and Prevention\/Infectious diseases society of America clinical practice guidelines: treatment of Drug-Susceptible tuberculosis. Clinical Infectious Diseases. Oxford University Press. 2016;63:e147\u201395.","DOI":"10.1093\/cid\/ciw376"},{"key":"11796_CR14","doi-asserted-by":"crossref","unstructured":"Floreani A, Bizzaro D, Shalaby S, Taliani G, Burra P. Sex disparity and drug-induced liver injury. Digestive and Liver Disease. Elsevier B.V. 2023;55;21\u20138.","DOI":"10.1016\/j.dld.2022.06.025"},{"key":"11796_CR15","doi-asserted-by":"crossref","unstructured":"Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Therapeutic Advances in Gastroenterology. SAGE Publications Ltd. 2023;16.","DOI":"10.1177\/17562848231163410"},{"key":"11796_CR16","doi-asserted-by":"crossref","unstructured":"Liu Q, Huang L, Yan H, Zong Z, Chen Z, Wu X et al. Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury. Front Pharmacol. 2024;15.","DOI":"10.3389\/fphar.2024.1406454"},{"issue":"4","key":"11796_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-777X.170499","volume":"7","author":"CT Costiniuk","year":"2015","unstructured":"Costiniuk CT, Gosnell BI, Manzini TC, Du Plessis CN, Moosa MYS. Tuberculous drug-induced liver injury and treatment re-challenge in human immunodeficiency virus co-infection. J Glob Infect Dis. 2015;7(4):151\u20136.","journal-title":"J Glob Infect Dis"},{"key":"11796_CR18","doi-asserted-by":"crossref","unstructured":"Kengo A, Nabeemeeah F, Denti P, Sabet R, Okyere-Manu G, Abraham P, Weisner L, Mosala MH, Tshabalala S, Scholefield J, Resendiz-Galvan JE. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024;68(5):e01583-23.","DOI":"10.1128\/aac.01583-23"},{"key":"11796_CR19","doi-asserted-by":"crossref","unstructured":"Arias L, Otwombe K, Waja Z, Tukvadze N, Korinteli T, Moloantoa T, Fonseca KL, Pillay N, Seiphetlo T, Ouchi-Vernet D, Siles A. SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen. Trials. 2023;24(1):435.","DOI":"10.1186\/s13063-023-07448-0"},{"issue":"10","key":"11796_CR20","doi-asserted-by":"publisher","first-page":"e0309034","DOI":"10.1371\/journal.pone.0309034","volume":"19","author":"D Evans","year":"2024","unstructured":"Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, Conradie F, et al. Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South africa: A cost-effectiveness analysis. PLoS ONE. 2024;19(10):e0309034.","journal-title":"PLoS ONE"},{"key":"11796_CR21","unstructured":"Hopkins University J. StAT-TB (Statin adjunctive therapy for TB): A phase 2b Dose-finding study of Pravastatin in adults with tuberculosis. 2019."},{"issue":"2","key":"11796_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ng1706","volume":"38","author":"AD Skol","year":"2006","unstructured":"Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38(2):209\u201313.","journal-title":"Nat Genet"},{"key":"11796_CR23","doi-asserted-by":"crossref","unstructured":"Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. British Journal of Clinical Pharmacology. Blackwell Publishing Ltd. 2018;84:2747\u201360.","DOI":"10.1111\/bcp.13722"},{"key":"11796_CR24","doi-asserted-by":"crossref","unstructured":"Chan SL, Chua AP, Aminkeng F, Chee CB, Jin S, Loh M, Gan SH, Wang YT, Brunham LR. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017;12(10):e0186200.","DOI":"10.1371\/journal.pone.0186200"},{"issue":"6","key":"11796_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/jhg.2016.10","volume":"61","author":"R Yuliwulandari","year":"2016","unstructured":"Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016;61(6):533\u20137.","journal-title":"J Hum Genet"},{"key":"11796_CR26","doi-asserted-by":"crossref","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J, DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug safety. 2009;32(1):55-68.","DOI":"10.2165\/00002018-200932010-00005"},{"key":"11796_CR27","doi-asserted-by":"crossref","unstructured":"Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. American Journal of Gastroenterology. Nature Publishing Group; 2014;109:950\u201366.","DOI":"10.1038\/ajg.2014.131"},{"key":"11796_CR28","unstructured":"WHO consolidated guidelines on. tuberculosis Module 4: Treatment Drug-resistant tuberculosis treatment 2022 update."},{"key":"11796_CR29","doi-asserted-by":"crossref","unstructured":"Wang N, Chen X, Hao Z, Guo J, Wang X, Zhu X, Yi H, Wang Q, Tang S. Incidence and temporal trend of antituberculosis drug\u2010induced liver injury: a systematic review and meta\u2010analysis. J Trop Med. 2022;2022(1):8266878.","DOI":"10.1155\/2022\/8266878"},{"key":"11796_CR30","doi-asserted-by":"crossref","unstructured":"Akkahadsee P, Jantharaksa S, Sawangjit R, Phumart P. Incidence, outcomes, and risk factors of antituberculosis drugs induced liver injury in Thailand: A retrospective cohort study. Pharma Practice. 2024;22(2):1-7.","DOI":"10.18549\/PharmPract.2024.2.2965"},{"key":"11796_CR31","doi-asserted-by":"crossref","unstructured":"Duarte R, Munsiff SS, Nahid P, Saukkonen JJ, Winston CA, Abubakar I, et al. Updates on the treatment of Drug-Susceptible and Drug-Resistant tuberculosis an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. American Thoracic Society; 2025;211:15\u201333.","DOI":"10.1164\/rccm.202410-2096ST"},{"issue":"8","key":"11796_CR32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/pds.3988","volume":"25","author":"Q Sun","year":"2016","unstructured":"Sun Q, Zhang Q, Gu J, Sun WW, Wang P, Bai C, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf. 2016;25(8):908\u201317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"11796_CR33","doi-asserted-by":"crossref","unstructured":"Lim J, Kim JS, Kim HW, Kim YH, Jung SS, Kim JW, Oh JY, Lee H, Kim SK, Kim SH, Lyu J. Metabolic disorders are associated with drug-induced liver injury during antituberculosis treatment: a multicenter prospective observational cohort study in Korea. InOpen Forum Infectious Diseases. US: Oxford University Press; 2023;10(8):ofad422.","DOI":"10.1093\/ofid\/ofad422"},{"key":"11796_CR34","doi-asserted-by":"crossref","unstructured":"Kumar R, Kumar A, Patel R, Prakash SS, Kumar S, Surya H et al. Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis. Indian Journal of Gastroenterology. Springer. 2024.","DOI":"10.1007\/s12664-024-01643-w"},{"key":"11796_CR35","doi-asserted-by":"crossref","unstructured":"Wang Y, Xie W. Drug-induced liver injury: an overview and update. Gastroenterology and Endoscopy. KeAi Communications Co. 2023;1:102\u20139.","DOI":"10.1016\/j.gande.2022.11.005"},{"issue":"7","key":"11796_CR36","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/liv.14896","volume":"41","author":"F Jiang","year":"2021","unstructured":"Jiang F, Yan H, Liang L, Du J, Jin S, Yang S, et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int. 2021;41(7):1565\u201375.","journal-title":"Liver Int"},{"key":"11796_CR37","doi-asserted-by":"publisher","unstructured":"Hosford JD, Von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA et al. Hepatotoxicity from antituberculous therapy in the elderly: A systematic review HHS Public Access. Tuberculosis (Edinb). 2015;95(2):112\u201322. Available from: https:\/\/doi.org\/10.1016\/j.tube","DOI":"10.1016\/j.tube"},{"key":"11796_CR38","doi-asserted-by":"crossref","unstructured":"D. Freire I, L. Fielding K, AJ Moore D. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?. PLoS One. 2023;18(5):e0286306.","DOI":"10.1371\/journal.pone.0286306"},{"key":"11796_CR39","doi-asserted-by":"crossref","unstructured":"Zhang F, Zhang F, Qin M, Li L. Alcohol consumption as a risk factor for anti-tuberculosis drug induced liver injury: A systematic review and meta-analysis. Microb Pathog. 2024;196:107003. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401024004704","DOI":"10.1016\/j.micpath.2024.107003"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:57:05Z","timestamp":1761299825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11796"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11796-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6596752\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Human Research Ethics Committee of the University of the Witwatersrand (Wits HREC: M240904). All study procedures were conducted in accordance with the Declaration of Helsinki and adhered to applicable national regulations and ethical guidelines governing research in South Africa. Written informed consent was obtained from all participants prior to their enrolment in the study or prior to collection of specimens that were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of anonymized data was obtained from all participants, including those enrolled in the cohort studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1400"}}